The reaction of 7-chloro-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) with each of sarcosine and (±)-pipecolinic acid afforded the corresponding N-(4-oxoquinolin-7-yl)-α-amino acids 8 and 9. Reductive lactamization of the latter with sodium dithionite gave hexahydropyrido[2,3-f ]quinoxaline (10) and octahydrodipyrido[1,2-a : 2,3-f ]quinoxaline (11) derivatives, respectively. Compounds 8 -11 and their homologs 1 -6, accessible from (S)-proline, (2S, 4R)-4-hydroxyproline and (S)-tetrahydroisoquinoline-3-carboxylic acid exhibit good to excellent antibacterial activities against E. coli and S. aureus.
Introduction
New drugs are desperately searched for in order to counteract the alarming increase in evolution of antimicrobial resistance to existing antibiotics. There is a continuing need for the discovery and development of new agents against resistant strains with broad therapeutic index [1] . Synthetic fluoroquinolones [2, 3] , e. g. ciprofloxacin [2] , represent a recent successful achievement towards the design and development of potent antiinfectious drugs. On the other hand, substituted quinoxalinones have become interesting compounds for study of their bioproperties such as antibacterial [4] and antitumor [5] activity. Quite recently, we have described the synthesis of heterocycles [a]-fused onto pyrido [2,3- f ]quinoxaline-3-carboxylic acids, exemplified by compounds 4 -6 via reductive lactamization of their respective acyclic fluoroquinolone precursors 1 -3 [6] . The heterocyclic derivatives 4 -6 exhibit excellent potential as antitumor therapeutic agents [6] In this study, we have investigated the antibacterial activity of compounds 1 -6, which were shown to 0932-0776 / 07 / 1100-1453 $ 06.00 © 2007 Verlag der Zeitschrift für Naturforschung, Tübingen · http://znaturforsch.com display good to excellent potency against Gram negative and Gram positive bacterial strains. These findings have prompted us to prepare an additional set of related heterocycles 8 -11 (Schemes 1 and 2) for further antibacterial testing.
Results and Discussion
Direct interaction between 7-chloro-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) with each of sarcosine and (±)-pipecolinic acid produced the respective N-(4-oxoquinolin-7-yl)-α-amino acids 8a, 9a which were converted into their methyl esters 8b, 9b upon reaction with diazomethane in ether (Scheme 1).
Reductive lactamization of 8a, 9a with sodium dithionite delivered the respective tri-and tetracyclic derivatives, namely hexahydro[2,3-f ]quinoxaline 10 and octahydrodipyrido[1,2-a: 2,3-f ]quinoxaline 11 (Scheme 2). This synthetic approach is similar to that described for compounds 1 -6 [6] and is analogous to the methodology recently reported [7] for the preparation of heterocyclic [c]-fused 3,4-di- Scheme 1. hydroquinoxalin-2-ones starting from N-(2-nitrophenyl)cyclic imino acids.
The spectral (IR, MS, NMR) and microanalytical data for the new compounds 8 -11 are in accordance with the assigned structures, and are given in the Experimental Section. Thus, the mass spectra of 8 -11 display the correct molecular ions for which the measured high-resolution (HRMS) data are in good agreement with the calculated values. The 1 H and 13 C signal assignments are based on DEPT and 2D (COSY, HMQC, HMBC) experiments wherein the associated spectra showed correlations that helped in assigning the various signals to the different carbon and their attached / neighboring hydrogen atoms.
Antimicrobial Activity
In vitro antibacterial screening results of compounds 1 -6 and 8 -11 have shown that all tested compounds exhibit good to excellent antimicrobial po- tency against both strains tested. Compound 6 is the most active derivative of this series, with MIC ≈ 2.5 µg/mL, against Staphylococcus aureus (representative of Gram-positive bacteria). On the other hand, compound 2 and its cyclized product 5 (and to a lesser extent 4 and 10) display excellent activity against Escherichia coli (representative of Gram-negative bacteria). In general, it can be concluded that those derivatives have stronger activity against E. coli, indicating a mechanism of action similar to fluoroquinolones. Moreover, the cyclized products seem to have better activity against E. coli as compared to S. aureus. The in vitro antibacterial data of the model compounds are given in Table 1 .
Experimental Section
The secondary α-amino acids sarcosine and (±)-pipecolinic acid, employed in this study, were of biochemical grades (Acros) and used as received. 2,4-Dichloro-5-fluoro-3-nitrobenzoic acid was purchased from Acros. Melting points (uncorrected) were determined on a Gallenkamp electrothermal melting temperature apparatus. 1 H and 13 C NMR spectra were recorded on a Bruker DPX-300 instrument with Me 4 Si as internal reference. EIMS spectra were obtained using a Finnigan MAT TSQ-70 spectrometer at 70 eV, ion source temperature = 200 • C. High-resolution MS-ESI data were obtained with a Bruker Bio TOF III instrument. IR spectra were recorded as KBr discs on a Nicolet Impact-400 FT-IR spectrophotometer. Microanalyses were performed at the Microanalytical Laboratory -Medicinal Chemistry Division, Faculty of Pharmacy, University of Jordan, Amman.
Pharmacological tests
The minimal inhibitory concentrations (MICs) were determined by the conventional broth dilution method using the two serial dilution technique. The standardization of bacterial test suspension was carried out according to the McFarland standard method as described by the National Committee for Clinical Laboratories Standard (NCCLS) (1993). Stock solutions of the test compounds were prepared using DMSO. Serial dilutions were prepared to obtain test concentrations ranging from 156 µg/mL to 0.3 µg/mL. Each tube was then inoculated with 0.1 mL of the cultured bacteria (containing approximately 1 to 2 × 10 8 CFU / mL), mixed and incubated at 37 • C for 24 h. Growth inhibition with concentrations of 156 µg/mL or lower were carried out in duplicates. All test tubes showing positive/negative growth were confirmed by the agar plate method. The results were recorded according to presence and absence of growth. The MICs were calculated as the average concentration of the test agent in the broth tubes showing consecutive positive and negative growth.
7-Chloro-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7)
This compound was prepared from 2,4-dichloro-5-fluoro-3-nitrobenzoic acid, ethyl 3-(N,N-dimethylamino)acrylate and cyclopropylamine by following literature procedures [8] .
7-[(Carboxymethyl) (methyl)amino]-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (8a)
A stirred mixture of sarcosine (0.80 g, 9 mmol), 7-chloro-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 7 (1.00 g, 3.1 mmol) and sodium hydrogen carbonate (1.50 g, 18 mmol) in 50 % aqueous ethanol (140 mL) was heated at 75 -80 • C under reflux conditions. The mixture slowly developed a light yellow color that changed into a bright yellow, then into a clear orange solution. The progress of the reaction was monitored by TLC and was completed within 20 -24 h. The orange solution was extracted with dichloromethane (50 mL) and the aqueous layer was separated, acidified with 3 N HCl to pH 6.5 and re-extracted with dichloromethane (50 mL). The aqueous layer was again separated, cooled and re-acidified with 3 N HCl to pH 3 -4, whereby the title compound was precipitated as a yellowish solid which was collected by suction filtration, washed with cold water (2 × 10 mL 
Methyl 1-cyclopropyl-6-fluoro-7-[(methoxycarbonylmethyl) (methyl)amino]-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate (8b)
To a fine powder of 8a (0.38 g, 1.0 mmol), suspended in cold diethyl ether (20 mL), was added portionwise a cold fresh ethereal diazomethane solution until evolution of nitrogen ceased. The reaction mixture was kept at 5 -10 • C for 20 min, and the solvent was then evaporated at r. t., whereby the title compound was obtained as a yellow solid. Yield of 8b: 0.34 g (83 %), m. 
(±)-7-(2-Carboxypiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid [(±)-9a]
A stirred mixture of (±)-pipecolinic acid (1.20 g, 9.3 mmol), 7 (1.0 g, 3.1 mmol) and sodium hydrogen carbonate (1.50 g, 18 mmol) in 50 % aqueous ethanol (140 mL) was heated at 85 -90 • C for 4 -5 days under reflux conditions. Work up of the resulting reaction mixture was followed as described for 8a above and produced the title compound as a light yellow solid which was recrystallized from ethanol. Yield of (±)-9a: 0. 
(±)-Methyl 1-cyclopropyl-6-fluoro-7-[2-(methoxycarbonyl) piperidin-1-yl]-8-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate [(±)-9b]
This compound was prepared via the reaction of (±)-9a (0.42 g, 1.0 mmol) with diazomethane in ether following the procedure described above for 8b. Yield of (±)-9b: 0.38 g (85 %), m. p. 181 -182 • C (dec. This compound was prepared by reduction of (±)-9a (0.42 g, 1.0 mmol) with sodium dithionite following the procedure described above for the preparation of 10; the reduction time was 25 min. following the addition of sodium dithionite. The product was recrystallized from methanol / chloroform ( 
